2014
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients
Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski Ł, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014, 1: e000064. PMID: 25332803, PMCID: PMC4189321, DOI: 10.1136/openhrt-2014-000064.Peer-Reviewed Original ResearchSecond-generation drug-eluting stentsPaclitaxel-eluting stentsDrug-eluting stentsSecond-generation EESCoronary artery diseaseMyocardial infarctionEnd pointArtery diseaseClinical trialsPrespecified safety end pointsStable coronary artery diseaseIncidence of MIFirst-generation drug-eluting stentsFirst-generation SESReduction of oddsEfficacy end pointSafety end pointTarget lesion revascularisationAcute coronary syndromeComposite end pointSafe drug-eluting stentCurrent clinical practiceLong-term safetyVessel revascularisationCardiac mortality
2013
The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial
Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 67-77. PMID: 24562805, PMCID: PMC3932775, DOI: 10.1177/2048872613507149.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsCoronary AngiographyDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesGated Blood-Pool ImagingHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPrognosisProspective StudiesRecombinant ProteinsTreatment OutcomeVentricular Function, LeftConceptsST-segment elevation myocardial infarctionLeft ventricular ejection fractionPaclitaxel-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionLV dysfunctionLV functionMyocardial infarctionIschaemia-driven target lesion revascularizationMajor adverse cardiovascular eventsNet adverse clinical eventsPrimary percutaneous coronary interventionBaseline LV dysfunctionIndex revascularization procedureAdverse cardiovascular eventsOutcomes of patientsTarget lesion revascularizationHigh-risk patientsSubstantial clinical benefitAdverse clinical eventsNormal LV functionPercutaneous coronary interventionVentricular ejection fractionLeft ventricular functionBare metal stentsMeta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovascular Interventions 2013, 6: 914-922. PMID: 24050859, DOI: 10.1016/j.jcin.2013.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationMajor adverse cardiac eventsAdverse cardiac eventsTarget lesion revascularizationLesion failureMyocardial infarctionLesion revascularizationCause mortalityCardiac eventsStent thrombosisStent typeEvent ratesTarget lesion failureClinical trial programException of diabetesIndividual patient dataIndividual clinical outcomesCardiac deathComposite endpointClinical outcomesSPIRIT IIClinical trialsCoronary implantationTrial program
2012
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing. Journal Of Invasive Cardiology 2012, 24: 444-50. PMID: 22954564.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsDrug-eluting stentsSegment late lossJapan RegistryLate lossUS patientsEES groupPrimary endpointSingle-arm multicenter studySecond-generation drug-eluting stentsFirst-generation drug-eluting stentsLower late lossTarget vessel failureAdverse cardiac eventsMid-term resultsCardiac eventsPES groupMulticenter studyJapanese patientsNeointimal volumeApposition ratePatientsStudy aimClinical programsImpact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years
Lansky AJ, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, Stone GW. Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. The American Journal Of Cardiology 2012, 110: 21-29. PMID: 22464212, DOI: 10.1016/j.amjcard.2012.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary AngiographyCoronary Artery DiseaseEverolimusFollow-Up StudiesHumansImmunosuppressive AgentsPaclitaxelProspective StudiesProsthesis DesignReproducibility of ResultsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsID-TLRAngiographic groupClinical followMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesDrug-eluting stent placementMajor adverse cardiovascular eventsBare metal stent implantationSPIRIT IIILandmark survival analysisSPIRIT III trialAdverse cardiovascular eventsSafety end pointCardiovascular event ratesIschemia-driven revascularizationMajor clinical outcomesPercutaneous coronary interventionDrug-eluting stentsRoutine AngiographicCardiovascular eventsCoronary revascularizationRevascularization ratesCoronary interventionIII trials
2011
Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovascular Interventions 2011, 4: 1209-1215. PMID: 22115661, DOI: 10.1016/j.jcin.2011.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsReference vessel diameterEverolimus-eluting stentsPercutaneous coronary interventionLong lesionsGroup BLesion lengthMACE rateCoronary interventionSmall vesselsGroup AStent typeShort lesionsAdverse cardiac eventsHigh-risk patientsPatient-level dataLarge vesselsLower ratesCOMPARE trialLesion revascularizationEfficacy outcomesAdverse eventsCardiac eventsIndependent predictorsImpact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictorsClinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2011, 7: 307-13. PMID: 21729832, DOI: 10.4244/eijv7i3a54.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionSegment restenosisYounger patientsElderly patientsLower incidenceSegment late lumen lossSegment late lossSPIRIT III trialTarget vessel failureLate lumen lossDrug-eluting stentsYears of ageThree-year resultsLower ratesAge-specific mechanismsStent assignmentAngiographic outcomesCoronary interventionIII trialsInducible ischaemiaEE patientsPE patientsLumen lossNeointimal responsePaclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction
Witzenbichler B, Wöhrle J, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Hood KL, Parise H, Lansky AJ, Nikolsky E, Mehran R, Stone GW. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. Circulation Cardiovascular Interventions 2011, 4: 130-138. PMID: 21364152, DOI: 10.1161/circinterventions.110.960245.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsTarget lesion revascularizationBare metal stentsHORIZONS-AMI trialDiabetic patientsDiabetes mellitusStent thrombosisMyocardial infarctionPercutaneous interventionIschemia-driven target lesion revascularizationMetal stentsAcute Myocardial Infarction trialHigh-risk diabetic patientsMyocardial Infarction trialPrimary percutaneous interventionInsulin-treated diabetesAcute myocardial infarctionAngiographic late lossComparable safety outcomesBinary restenosisHarmonizing OutcomesLesion revascularizationNondiabetic patientsAngiographic restenosisThree-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)
Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, Stone GW. Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial). The American Journal Of Cardiology 2011, 107: 841-848. PMID: 21255760, DOI: 10.1016/j.amjcard.2010.10.068.Peer-Reviewed Original ResearchConceptsTarget vessel failure rateSPIRIT III trialXIENCE VIII trialsClinical outcomesLow major adverse cardiac event rateMajor adverse cardiac event ratesAdverse cardiac event ratesMajor adverse cardiac eventsTAXUS paclitaxel-eluting stentAdverse cardiac eventsCardiac event rateCoronary artery lesionsLong-term complicationsPaclitaxel-eluting stentsThree-year resultsLesion revascularizationArtery lesionsCardiac eventsComplication rateStent thrombosisTreatment armsClinical benefitTaxus stentSubset analysisLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial). The American Journal Of Cardiology 2011, 107: 833-840. PMID: 21247538, DOI: 10.1016/j.amjcard.2010.10.069.Peer-Reviewed Original ResearchMeSH KeywordsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsLogistic ModelsMaleMiddle AgedPaclitaxelProspective StudiesSingle-Blind MethodSirolimusSurvival RateTreatment OutcomeTubulin ModulatorsUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiovascular eventsSPIRIT III trialAdverse cardiovascular eventsCardiovascular eventsIII trialsPrimary clinical end pointLimited long-term dataTarget lesion revascularizationTarget vessel failureEvent-free survivalClinical end pointsEverolimus-Eluting StentsLong-term safetyLesion revascularizationCardiac deathCoronary arteryMyocardial infarctionSPIRIT IIClinical trialsEfficacy profileUnited States sitesLandmark analysisTerm safetyXIENCE VStrut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction
Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ, Mehran R, Stone GW. Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction. Circulation 2011, 123: 274-281. PMID: 21220730, DOI: 10.1161/circulationaha.110.963181.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsOptical coherence tomographyStrut coverageCoherence tomographyBMS lesionsMyocardial infarctionPE lesionsStent strutsMetal stentsPrimary percutaneous coronary interventionAcute Myocardial Infarction trialMyocardial Infarction trialPrespecified end pointElevation myocardial infarctionIndependent core laboratoryPercutaneous coronary interventionStent strut coverageAcute myocardial infarctionSubsequent stent thrombosisDrug-eluting stentsFormal substudyHarmonizing OutcomesStent assignment
2010
Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, Stone GW. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6 Suppl J: j44-52. PMID: 21930490, DOI: 10.4244/eijv6supja8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPeriprocedural myocardial infarctionSide branch occlusionBranch occlusionMyocardial infarctionStent placementDrug-eluting stent placementIndependent angiographic core laboratoryPaclitaxel-eluting stent placementLong-term adverse outcomesSPIRIT III trialPaclitaxel-eluting stentsAngiographic core laboratoryThree-year resultsLower ratesSide branchesEES armIII trialsMI ratesIndependent predictorsClinical outcomesAdverse outcomesProcedural angiogramsGrade 0Stent typeCore laboratoryClinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Investigators S. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1220-1228. PMID: 21232715, DOI: 10.1016/j.jcin.2010.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicAspirinClopidogrelConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsProportional Hazards ModelsRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorSirolimusTiclopidineTime FactorsConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsAdverse cardiac eventsTarget vessel failureCardiac eventsMyocardial infarctionSPIRIT IIProbable stent thrombosisAcademic Research ConsortiumEverolimus-eluting stentsVessel failureSignificant reductionLesion revascularizationPES patientsRevascularization eventsIII trialsClinical outcomesEE patientsStent thrombosisPooled analysisCumulative ratePersistent reductionSPIRIT IIIPatientsStentsComparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, Stone GW. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1229-1239. PMID: 21232716, DOI: 10.1016/j.jcin.2010.09.014.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary Artery BypassCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleHumansImmunosuppressive AgentsKaplan-Meier EstimateMaleMiddle AgedPaclitaxelRandomized Controlled Trials as TopicSirolimusTime FactorsUnited StatesConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionSPIRIT IV trialTarget lesion revascularizationVessel myocardial infarctionLesion revascularizationMultivessel diseaseMultivessel interventionAbsolute benefitMyocardial infarctionOptimal revascularization strategySingle-vessel interventionDe novo lesionsReference vessel diameterEverolimus-ElutingMultilesion interventionEfficacy outcomesNovo lesionsRevascularization strategyCoronary diseaseClinical outcomesCoronary arteryClinical safetySingle lesionRandomized comparison of everolimus-eluting and paclitaxel-eluting stents: pooled analysis of 3-year clinical outcomes from the Spirit II and III Trials
Lansky A, Hermiller J, Applegate R, Caixeta A, Gordon P, Ruygrok P, Doostzadeh J, Miquel-Hebert K, Veldhof S, Sood P, Su X, Sudhir K, Serruys P, Stone G. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: pooled analysis of 3-year clinical outcomes from the Spirit II and III Trials. Cardiovascular Revascularization Medicine 2010, 11: 277. DOI: 10.1016/j.carrev.2010.03.028.Peer-Reviewed Original ResearchSelection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Lansky AJ, Mehran R. Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2010, 56: 1597-1604. PMID: 20888162, DOI: 10.1016/j.jacc.2010.08.608.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsDrug-eluting stentsElevation myocardial infarctionRisk factorsMyocardial infarctionClinical benefitVersus Bare-Metal StentsAbsolute incremental benefitHORIZONS-AMI trialBaseline risk factorsReference vessel diameterAngiographic Follow-upAbsolute treatment effectLesion revascularizationTLR proceduresTLR rateDiabetes mellitusIndependent predictorsRisk strataFollow-upRisk groupsHigh riskAntirestenotic propertiesComparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6: 437-46. PMID: 20884430, DOI: 10.4244/eij30v6i4a75.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsClinical outcomesStent typeMajor adverse cardiac eventsTwo-year event ratesSPIRIT IIIPaclitaxel-eluting coronary stentsSPIRIT III trialYear clinical outcomesAdverse cardiac eventsCardiac eventsIII trialsPE groupTwo-vesselPatientsEvent ratesCoronary stentsTrialsVessel treatmentStentsOutcomesVesselsSignificant interactionStentingLesionsIncidence, Mechanisms, Predictors, and Clinical Impact of Acute and Late Stent Malapposition After Primary Intervention in Patients With Acute Myocardial Infarction
Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Dressler O, Parise H, Mehran R, Stone GW. Incidence, Mechanisms, Predictors, and Clinical Impact of Acute and Late Stent Malapposition After Primary Intervention in Patients With Acute Myocardial Infarction. Circulation 2010, 122: 1077-1084. PMID: 20805433, DOI: 10.1161/circulationaha.109.906040.Peer-Reviewed Original ResearchConceptsAcute stent malappositionPaclitaxel-eluting stentsBare metal stentsLate stent malappositionPES-treated lesionsStent malappositionPositive remodelingMyocardial infarctionST-segment elevation myocardial infarction (STEMI) patientsST-segment elevation myocardial infarctionEquivalent bare metal stentsAcute Myocardial Infarction trialElevation myocardial infarction patientsASM areaExternal elastic membrane areaIntravascular ultrasound substudyPeri-stent plaquePrimary stent implantationMyocardial Infarction trialNative coronary lesionsElevation myocardial infarctionAcute myocardial infarctionMyocardial infarction patientsSubset of lesionsExternal elastic membraneIntravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents
Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Leon MB, Moses JW, Stone GW. Intravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents. The American Journal Of Cardiology 2010, 106: 952-957. PMID: 20854956, DOI: 10.1016/j.amjcard.2010.05.024.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsIntravascular ultrasound findingsSirolimus-eluting stentsUltrasound findingsStent fractureExternal elastic membrane areaClinical trial cohortSimilar frequencyComplete stent fracturePE fractureTrial cohortInstitutional cohortIVUS findingsStent lengthDistal fragmentIVUS featuresIVUS analysisCalcified plaquesStent fragmentsPatientsStrut fractureStentsMalalignmentCohortFractures